urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2017-5-3-68-78urovest-163Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEБОТУЛИНИЧЕСКИЙ ТОКСИН В ЛЕЧЕНИИ ИНТЕРСТИЦИАЛЬНОГО ЦИСТИТАBOTULINUM TOXIN A FOR THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROMEhttps://orcid.org/0000-0001-8335-2578МедведевВ. Л.MedvedevV. L.

Медведев Владимир Леонидович, доктор медицинских наук, профессор, заведующий кафедрой урологии ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России, заместитель главного врача по урологии, руководитель уронефрологического центра ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского» Минздрава Краснодарского края. 

Краснодар.

Medvedev Vladimir Leonidovich, doctor of Medicine, professor and Chairman Department of Urology Kuban State Medical University, head of the Urology and Nephrology Center, the Chief of the urological Service of Krasnodar regional hospital №1, chief specialist of transplantology of Krasnodar region, chief of the Urology Department №2 of Krasnodar Regional Hospital № 1.

Krasnodar.

medvedev_vl@mail.ruhttps://orcid.org/0000-0001-6657-1496ЛепетуновС. Н.LepetunovS. N.

Лепетунов Сергей Николаевич, врач-уролог ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского» Минздрава Краснодарского края.

 

Lepetunov Sergey Nikolaevich, urologist of Urology Department №2 of Krasnodar Regional Hospital № 1. 

Krasnodar.

lepetunov@gmail.comФГБОУ ВО «Кубанский государственный медицинский университет» МЗ РФ; ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского» МЗ Краснодарского края.РоссияKuban State Medical University; State Budgetary Healthcare Institution «Research Institution - Regional Clinical Hospital № l of prof. S.V. Ochapovskogo».Russian FederationГБУЗ «Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского» МЗ Краснодарского края.РоссияState Budgetary Healthcare Institution «Research Institution - Regional Clinical Hospital № l of prof. S.V. Ochapovskogo».Russian Federation201710102017536878Copyright © Медведев В.Л., Лепетунов С.Н., 20172017Медведев В.Л., Лепетунов С.Н.Medvedev V.L., Lepetunov S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/163

Синдром болезненного мочевого пузыря/интерстициальный цистит является хроническим заболеванием, которое отрицательно влияет на качество жизни. Существуют различные теории этиологии и патогенеза заболевания. Интерстициальный цистит может не диагностироваться в течение многих лет, потому что ряд заболеваний мочевого пузыря имеет в своей клинической картине болевой синдром. Кроме того, симптоматика значительно различается у каждого пациента, и ни одно лечение не доказало свою эффективность. Цель терапии интерстициального цистита на сегодняшний день заключается в уменьшении симптомов, чтобы улучшить качество жизни пациента. Внутрипузырный ботулинический токсин A становится потенциально новым фармакологическим методом лечения для синдрома болезненного мочевого пузыря/интерстициального цистита. Цель нашего обзора – оценить эффективность внутрипузырной ботулинотерапии.

Interstitial Cystitis/Bladder Pain Syndrome is a chronic and debilitating condition that negatively impacts quality of life. Several causes have been postulated in the pathogenesis of this condition; however, the etiology remains unknown. Interstitial сystitis may go undiagnosed for many years because the condition often co-exists with other chronic pain syndromes. Furthermore, the symptoms of Bladder Pain Syndrome vary considerably across patients, therefore no one treatment has shown to be consistently effective in providing relief. Thus, the goal of management of interstitial сystitis remains to provide relief of symptoms in order to improve a patient’s quality of life. intravesical Botulinum toxin A is emerging as a potential new pharmacologic treatment for interstitial сystitis refractory to conventional treatment modalities. The aim of our short review is to assess the efficacy of intravesical Botulinum toxin A in Bladder Pain Syndrome.

ботулинический токсинсиндром болезненного мочевого пузыряинтерстициальный циститвнутрипузырная терапияBotulinum toxinbladder pain syndromeinterstitial сystitisintravesical treatmentReferencesvan de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, et al. Diagnos c criteria, classifi ca on, and nomenclature for painful bladder syndrome/inters al cys s: an ESSIC proposal. Eur Urol. 2008;53(1):60-7. doi: 10.1016/j.eururo.2007.09.019van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60-7. doi: 10.1016/j.eururo.2007.09.019Hanno PM, Burks D, Clemens JQ, Dmochowski R, Erickson D, Fitzgerald MP. AUA guideline for the diagnosis and treatment of inters al cys s/bladder pain syndrome. J Urol. 2011;185(6):2162–70. doi: 10.1016/j.juro.2011.03.064Hanno PM, Burks D, Clemens JQ, Dmochowski R, Erickson D, Fitzgerald MP. AUA guideline for the diagnosis and treatment of inters al cys s/bladder pain syndrome. J Urol. 2011;185(6):2162–70. doi: 10.1016/j.juro.2011.03.064Зайцев А.В., Шаров М.Н., Пушкарь Д.Ю., Ходырева Л.А., Дударева А.А. Хроническая тазовая боль. Клинические рекомендации. Москва; 2016.Zaytsev AV, Sharov MN, Pushkar DYu, Khodyreva LA,. Dudareva AA. Chronic pelvic pain. Clinical recommenda ons. Moscow; 2016. (In Russ.)Коган М.И., Белоусов И.И., Сизонов В.В. Применение ботулинического токсина типа А в коррекции симптомов нарушенного мочеиспускания у детей и взрослых. Эффективная фармакотерапия. 2011;44:10-Kogan MI, Belousov II, Sizonov VV. The use of botulinum toxin type A in the correc on of symptoms of impaired urina on in children and adults. Eff ek vnaya farmakoterapiya. 2011;44:10-15. (In Russ.)5. Jabbari B. Botulinum Toxin Treatment of Pain Disorders. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.Jabbari B. Botulinum Toxin Treatment of Pain Disorders. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has an noccep ve eff ects in trea ng inters al cys s. Urology. 2004;64:871–5. doi: 10.1016/j.urology.2004.06.073Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has an noccep ve eff ects in trea ng inters al cys s. Urology. 2004;64:871–5. doi: 10.1016/j.urology.2004.06.073Jhang JF, Jiang YH, Kuo HC. Poten al therapeu c eff ect of intravesical botulinum toxin type A on bladder pain syndrome/inters al cys s. Int J Urol. 2014;21(1):49-55. doi: 10.1111/iju.12317.Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(1):4955. doi: 10.1111/iju.12317.Giannantoni A, Costan ni E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injec ons in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49:704. doi: 10.1016/j.eururo.2005.12.002Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49:704. doi: 10.1016/j.eururo.2005.12.002Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic inters al cys s: results of a pilot study. Surgeon. 2007;5(6):331–3. doi: 10.1016/ S1479-666X(07)80084-9Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon. 2007;5(6):331–3. doi: 10.1016/S1479-666X(07)80084-9Carl S, Grosse J, Laschke S. Treatment of inters al cys s with botulinum toxin type A. Eur Urol. 2007;6:248. doi: 10.1016/S1569-9056(07)60896-3Carl S, Grosse J, Laschke S. Treatment of interstitial cystitis with botulinum toxin type A. Eur Urol. 2007;6:248. doi: 10.1016/S1569-9056(07)60896-3Liu HT, Kuo HC. Intravesical botulinum toxin A injec ons plus hydrodistension can reduce nerve growth factor produc on and control bladder pain in inters al cys s. Urology. 2007;70(3):463–8. doi: 10,1016 / j.urology.2007.04.038Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463–8. doi: 10.1016/j.urology.2007.04.038Giannantoni A, Porena M, Costan ni E, Zucchi A, Mearini L. Botulinum A toxin intravesical injec on in pa ents with painful bladder syndrome: 1-year follow-up. J Urol. 2008;179(3):1031–4. doi: 10,1016 / j.juro.2007.10.032Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow-up. J Urol. 2008;179(3):1031–4. doi: 10.1016/j.juro.2007.10.032Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injec ons plus hydrodistension with hydrodistension alone for the treatment of refractory inters albcys s/painful bladder syndrome. BJU Int. 2009;104:657–61. doi: 10.1111/j.1464410X.2009.08495.xKuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistension with hydrodistension alone for the treatment of refractory interstitialbcystitis/painful bladder syndrome. BJU Int. 2009;104:657–61. doi: 10.1111/j.1464410X.2009.08495.xEl-Bahnasy AE, Farahat YA, El-Bendary M, Mourad SA. Randomized controlled trial of bacillus Calme eGuerin and botulinum toxin-A for the treatment of refractory inters al cys s. UroToday Int J. 2009;2:2–2. doi:10.3834/uij.1944-5784.2008.12.06.El-Bahnasy AE, Farahat YA, El-Bendary M, Mourad SA. Randomized controlled trial of bacillus CalmetteGuerin and botulinum toxin-A for the treatment of refractory interstitial cystitis. UroToday Int J. 2009;2:2–2. doi:10.3834/uij.1944-5784.2008.12.06Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two -year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Current Drug Delivery. 2010;7(1):1-4Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Current Drug Delivery. 2010;7(1):1-4Rasheed T, Farahat A, Bahnasy M, Bindary A, Tatawy H. A prospective randomized study of intravesical pentosan polysulfate and botulinum toxin-A for the treatment of painful bladder syndrome/interstitial cystitis. Eur Urol Suppl. 2010;9(2):641.Rasheed T, Farahat A, Bahnasy M, Bindary A, Tatawy H. A prospec ve randomized study of intravesical pentosan polysulfate and botulinum toxin-A for the treatment of painful bladder syndrome/inters al cys s. Eur Urol Suppl. 2010;9(2):641.Pinto R, Lopes T, Frias B, Silva A, Silva JA, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):366–8. doi: 10.1016/j.eururo.2010.02.031Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, Cruz C, Cruz F, Dinis P. Trigonal injec on of botulinum toxin A in pa ents with refractory bladder pain syndrome/inters al cys s. Eur Urol. 2010;58(3):366–8. doi: 10.1016/j.eururo.2010.02.031Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for Interstitial cystitis/painful bladder syndrome. Neurourol Urodyn. 2011;30:93–6. doi: 10,1002 / nau.20946Go sch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for Inters al cys s/painful bladder syndrome. Neurourol Urodyn. 2011;30:93–6. doi: 10.1002/nau.20946Chung SD, Kuo YC., Kuo HC. Intravesical onabotulinumtoxin A injections for refractory painful bladder syndrome. Pain Physician. 2012;15:197-202.Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxin A injec ons for refractory painful bladder syndrome. Pain Physician. 2012;15:197-202.Kuo HC. Repeated Onabotulinumtoxin-A Injections Provide Better Results than Single Injection in Treatment of Painful Bladder Syndrome. Pain Physician. 2013;16:E15-E23.Kuo HC. Repeated Onabotulinumtoxin-A Injec ons Provide Be er Results than Single Injec on in Treatment of Painful Bladder Syndrome. Pain Physician. 2013;16:E15E23.Lee CL, Kuo HC. Long-Term Effi cacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injec ons Plus Hydrodisten on in the Treatment of Inters al Cys s/ Bladder Pain Syndrome. Toxins. 2015;7(10);4283-4293. doi: 10.3390/toxins7104283Lee CL, Kuo HC. Long-Term Effi cacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injec ons Plus Hydrodisten on in the Treatment of Inters al Cys s/ Bladder Pain Syndrome. Toxins. 2015;7(10);4283-4293. doi: 10.3390/toxins7104283Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment – A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609-14. doi: 10.1002/nau.22760Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injec ons reduce bladder pain of inters al cys s/bladder pain syndrome refractory to conven onal treatment – A prospec ve, mul center, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609-14. doi: 10.1002/nau.22760Lorenzo L, Bonillo MA, Arlandis S, Mar nez-Cuenca E, Marzullo L et al. Hydrodistension plus Onabotulinumtoxin A in bladder pain syndrome refractory to conserva ve treatments. Actas Urol Esp. 2016;40(5):303-8. doi: 10.1016/j.acuro.2015.12.011Lorenzo L, Bonillo MA, Arlandis S, Mar nez-Cuenca E, Marzullo L, Broseta E, Boronat F. Hydrodistension plus Onabotulinumtoxin A in bladder pain syndrome refractory to conserva ve treatments. Actas Urol Esp. 2016;40(5):303-8. doi: 10.1016/j.acuro.2015.12.011Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, et al. Botulinum toxin type A injec on for refractory inters al cys s: A randomized compara ve study and predictors of treatment response. Int J Urol. 2015;22(9):835-41. doi: 10.1111/iju.12833Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Homma Y. Botulinum toxin type A injec on for refractory inters al cys s: A randomized compara ve study and predictors of treatment response. Int J Urol. 2015;22(9):835-41. doi: 10.1111/iju.12833Saraswat I, Lawrentschuk N. Botulinum Toxin A in the Treatment of Inters al Cys s/Bladder Pain Syndrome: A Short Review. J Urol Res. 2015;2(1):1021.Saraswat I, Lawrentschuk N. Botulinum Toxin A in the Treatment of Inters al Cys s/Bladder Pain Syndrome: A Short Review. J Urol Res. 2015;2(1):1021.

The authors declare that there are no conflicts of interest present.